XXXX increases @entity413 uptake in the brain of young and adult @entity35 .

@entity2727 @entity146 @entity71 @entity7541 @entity880 @entity35 @entity413
BACKGROUND: @entity2727 ( @entity7541 ) is the drug of choice for pharmacological treatment of @entity71 . Studies have pointed to the role of @entity413 and @entity880 as well as in the action mechanisms of drugs used to treat these @entity146 . Thus, this study aims to evaluate the effects of @entity7541 administration on @entity880 release and @entity413 uptake in the brains of young and adult @entity35 . METHODS: @entity7541 (1.0, 2.0 and 10.0mg/kg) or saline was injected in young and adult @entity35 male @entity35 either acutely (once) or chronically (once daily for 28 days). Then, the levels of @entity880 release and @entity413 uptake were assessed in the prefrontal cortex, hippocampus, striatum, cerebellum and cerebral cortex. RESULTS: Chronic @entity7541 treatment increased @entity413 uptake at the dose of 10.0mg/kg in the prefrontal cortex and striatum, and at the dose of 2.0mg/kg in the cerebral cortex of young @entity35 . In adult @entity35 , an increase in @entity413 uptake was observed after acute administration of @entity7541 at the dose of 10.0mg/kg in the prefrontal cortex. After chronic treatment, there was an increase in @entity413 uptake with @entity7541 doses of 2.0 and 10.0mg/kg in the prefrontal cortex, and at an @entity7541 dose of 2.0mg/kg in the striatum of adult @entity35 . The @entity880 release did not change with either acute or chronic treatments in young or adult @entity35 . CONCLUSIONS: These findings indicate that @entity7541 increases @entity413 consumption in the brain, and that these changes are dependent on age and posology.
